WASHINGTON – The Consumer Healthcare Products Association (CHPA) announced the election of two new members to the CHPA Board of Directors during the association’s virtual November meeting. Newly elected CHPA board members include:
- Tim Grannan, president, Blistex Inc.
- Don Kerrigan, president, North America, The Nature’s Bounty Co.
Kerrigan was also elected to serve on the CHPA board’s executive committee.
“CHPA is delighted to welcome Tim and Don to its board of directors,” said CHPA president and CEO, Scott Melville. “CHPA’s expanded scope includes all three categories of personal healthcare – over-the-counter (OTC) medicines, dietary supplements, and consumer medical devices – and these board appointments reflect the broad spectrum of companies we represent.”
Paul Gama, president of Personal Health Care for The Procter & Gamble Company, will continue serving as CHPA’s board chair until the Annual Executive Conference being held March 21-23, 2021.
“As Americans increasingly prioritize self-care for their health and wellness, the CHPA board plays an essential role in establishing our industry’s priorities and guiding the work of the association,” continued Melville. “We are fortunate to have industry executives like Don, Tim, and Paul volunteer to share their expertise and further elevate the governance of our association as well as the role of consumer healthcare in America.”
Also approved at the meeting were two new members to the CHPA Educational Foundation board, including:
- Jason Milligan, marketing director, Oral Health, GSK Consumer Health
- Daniella Foster, vice president and Global Head, Public Affairs & Sustainability Consumer Health, Bayer Consumer Health
During the meeting, John Troup, CHPA vice president of Scientific Affairs and Dietary Supplements also issued the following statement on the statement from the American Medical Association (AMA) calling for “more stringent” regulation of dietary supplements:
“Dietary supplements in the U.S. are regulated products subject to manufacturing, labeling, marketing, and adverse event reporting rules established and enforced by the Food and Drug Administration (FDA) and Federal Trade Commission (FTC) under the Dietary Supplement Health and Education Act (DSHEA) of 1994. Today’s American Medical Association (AMA) call for more stringent regulation and more FDA enforcement has many parallels to calls from the supplement industry – including members of the Consumer Healthcare Product Association (CHPA) – who believe DSHEA needs to be modernized and strengthened.
“More than 25 years after the passage of DSHEA, the dietary supplements market has outgrown and outpaced the regulatory framework. Modernization is an important public health issue as bad actors continue to sell adulterated or misbranded dietary supplement products. CHPA is also advocating for increased resources for FDA to support more enforcement and new regulatory tools. Improvements such as mandatory product listing and other modernizations can help FDA to quickly identify and remove potentially hazardous and adulterated products from the market while also ensuring products meet quality standards. We look forward to collaborating with FDA and other stakeholders, including AMA, on proposals to enhance quality and oversight.
“When used appropriately, dietary supplements can play an important role in personal healthcare by filling nutritional gaps, supporting certain condition-specific needs, promoting healthy body functions, and contributing to overall wellness. Consumers should always carefully read Supplements Facts labels for ingredients and instructions for use. Labels must bear appropriate ingredient and nutrition information and should not claim to treat or cure diseases. Consumers should always seek out reputable companies and be wary of supplements that make claims which are ‘too good to be true’. Learn more from the CHPA Educational Foundation.”